Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 519-527

  Warnke, Clemens ^a,b   Stüve, Olaf ^c,d   Hartung, Hans Peter ^a   Fogdell Hahn, Anna ^b   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

FTY720; Oral drug; Spingosine 1 phosphate receptor

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

ACRANIA; ASYSTOLE; ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BONE DISEASE; BOWEN DISEASE; BRADYCARDIA; BRAIN MALFORMATION; BRAIN SIZE; BREAST CANCER; BRONCHITIS; CONGENITAL HEART DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; EMBRYOPATHY; EXPANDED DISABILITY STATUS SCALE; FALLOT TETRALOGY; FATIGUE; FORCED EXPIRATORY VOLUME; HEART RATE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; MELANOMA; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; POSTMARKETING SURVEILLANCE; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENICITY; TIBIA MALFORMATION; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY;

EID: 80955160568     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520-532.
2. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003;126(Pt 2):433-437.
3. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology. 2011;77(3):257-263.
4. Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011;11(3):351-362.
5. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335-343.
6. Chard DT, Geurts JJ. Predicting the development of multiple sclerosis: is gray matter a missing piece of the puzzle? Neurology. 2011;77(3):210-211.
7. Wiendl H, Toyka KV, Rieckmann P, Gold R, Har tung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449-1463.
8. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007;356(25):2622-2629.
9. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64(8):1336-1342.
10. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
11. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
12. Warnke C, Adams O, Gold R, et al. Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification? Nervenarzt. 2011;82(4):475-480. [German]
13. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol. 2010;67(8):923-930.
14. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438-446.
15. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924-933.
16. Sandrock AHC, Richman S, Natarajan A, et al. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Paper presented at: The 63rd Annual Meeting of the American Academy of Neurology; 2011 Apr 9-16; Honolulu, Hawaii.
17. US Food and Drug Administration (FDA). FDA approves first oral drug to reduce MS relapses [press release]. Sep 22, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm. Accessed June 1, 2011.
18. European Medicines Agency (EMA). Assessment report: Gilenya. Doc Ref: EMA/108602/2011. February 17, 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assess ment_report/human/002202/WC500104529.pdf. Accessed June 1, 2011.
19. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites: Part 11, a potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo). 1994;47(2):208-215.
20. Novartis Pharmaceutical Corporation. Prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf. Accessed June 1, 2011.
21. Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology. 2011;76 (8 Suppl 3):S3-S8.
22. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010;6(7): 373-382.
23. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-360.
24. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453-21457.
25. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346-349.
26. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58(6):840-846.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11): 1444-1452.
28. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
29. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
30. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520-529.
31. ClinicalTrials.gov [database online]. Bethesda, MD; US National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/results?term=fingolimod+AND+multiple+sclerosis. Accessed June 1, 2011.
32. Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler. 2011. In press.
33. Collins W, Francis G, Koren, et al. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Paper presented at: The 63rd Annual Meeting of the American Academy of Neurology; 2011 Apr 9-16; Honolulu, Hawaii.
34. Kieseier BC, Wiendl H. Transforming multiple sclerosis trials into practical reality. Lancet Neurol. 2011;10(6):493-494.
35. Turner AP, Williams RM, Sloan AP, Haselkorn JK. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol. 2009;54(1):116-121.
36. Pinschewer DD, Brinkmann V, Merkler D. Impact of sphingosine 1-phosphate modulation on immune outcomes. Neurology. 2011; 76 (8 Suppl 3):S15-S19.
37. Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76(8 Suppl 3): S20-S27.
38. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011;76(14):1214-1221.
39. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63(10):1383-1387.
40. Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69(2):408-413.